Latest Content

High-profile infanticide trial fuels debate over postpartum illness, malpractice claims, and whether psychiatrists should be judged for patients’ crimes rather than care quality.

Plasma P-tau217 blood tests match amyloid PET for early Alzheimer pathology, offering scalable, noninvasive detection and forecasting cognitive decline risk years ahead.

A psychiatrist shares how mindfulness, vulnerability, and shared presence strengthen therapy, reduce burnout, and reshape modern psychiatric care.

Impaired self-awareness is a frequent and impactful consequence of traumatic brain injury (TBI), occurring in as many as 40% to 80% of individuals with moderate-to-severe TBI. Deficits in self-awareness can negatively impact goal setting, treatment compliance, and motivation for therapy. Addressing this impairment through targeted interventions can improve rehabilitation outcomes, psychosocial adjustment, and community participation.

Bipolar depression does not have a single face. Through one patient’s journey, this case-based reflection explores 5 distinct presentations and how each can shape clinical recognition and treatment.

Experts unpack benzodiazepines in seniors: Beers Criteria, fall risk, Alzheimer bias, and practical low-dose, mindful prescribing strategies.

Why behavioral health integration still stalls: workforce shortages, cross-training wins, and collaborative care tips from frontline

How online scams and AI deepfakes prey on people with schizophrenia, triggering relapse—plus practical clinician screening and safety planning tips.

Clinicians weigh benzodiazepine benefits against dependence fears, with expert guidance on safe prescribing, withdrawal tapering, and long-term anxiety treatment choices.

See the latest in this psychiatric news roundup.

FDA clears a simple pTau217 blood test that helps clinicians rule in or out Alzheimer’s amyloid earlier, expanding access beyond PET/CSF.

In this CME article, explore why migraine often coexists with depression and anxiety, and get practical tips for diagnosis, prevention, and smarter prescribing.

Clearmind patents MDMA plus PEA combo aiming to boost PTSD, anxiety and eating-disorder therapy as FDA issues new psychedelic trial guidance.